Skip to main content
Fig. 7 | Molecular Cancer

Fig. 7

From: Targeting CDK7 suppresses super enhancer-linked inflammatory genes and alleviates CAR T cell-induced cytokine release syndrome

Fig. 7

Schematic illustration of the protection of THZ1 during CRS treatment. Overwhelming release of cytokines in activated macrophages contributes to severe CRS. THZ1 can efficiently alleviate the magnitude of cytokine release by binding with CDK7 to reduce the phosphorylation of RNA Pol II after exposure to stimulation, which restricts the massive transcription of inflammatory genes and related transcriptional factors. Among these genes, STAT1 and IL1 are expected to be the key regulator and effector respectively because their transcriptional activities are under the control of super enhancer and influence a variety of crucial downstream molecules such as IL-6. Thus, targeting CDK7 provides a promising candidate for CRS treatment as a relatively broad-spectrum inhibitor

Back to article page

Molecular Cancer

ISSN: 1476-4598